Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2008

View Archived Issues

Ad5-CMV-NIS gene therapy enters dose-finding phase I study for prostate cancer

Bayer's PDE9 inhibitor improves memory deficits in animal models

Metallocomplex targeting iron metabolism novel approach against Pseudomonas infection

Retargeted adenovirus vector active in preclinical cancer models

New oncolytic agents disclosed in recent patent literature

Phase II data from H5 influenza vaccine trial confirms safety and immunogenicity

ISTA reports phase III results for topical Xibrom in patients undergoing cataract surgery

AVI files INDs for Ebola virus and Marburg virus treatment trials

Maas Biolab's intrathecal ciclosporin advances to phase II for ALS treatment

AC Immune selected as Technology Pioneer 2009 and advances AD program

Prezista receives expanded E.U. MA for treatment-experienced HIV patients

Erbitux sBLA for advanced non-small cell lung cancer submitted to FDA

Novel antithrombotic agents described in recent Boehringer Ingelheim patent

Recent GSK and Biolipox patents claim novel agents for respiratory disorders

FDA Advisory Committee recommends approval of Bausch & Lomb's besifloxacin

Amylin and Lilly provide update on FDA Byetta monotherapy submission

AstraZeneca and Targacept present top-line results from phase IIb AZD-3480 trial

Novel drug-loaded microparticles tested in experimental cardiac dysfunction

FDA grants approval to DOR BioPharma to initiate phase I/II clinical trial of DOR-201

CyDex receives FDA orphan drug designation for melphalan

Phase I data and preclinical activity of KW-2449 against leukemia described

FDA Advisory Committee recommends approval of Genzyme's Synvisc-One

Kuvan receives marketing approval in the E.U. for hyperphenylalaninemia

Ablynx initiates phase I study with novel antithrombotic Nanobody

NF-kappaB inhibitor V-1810 induces multiple myeloma cell death

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...